Form 8-K - Current report:
SEC Accession No. 0001104659-25-010729
Filing Date
2025-02-10
Accepted
2025-02-10 07:22:01
Documents
15
Period of Report
2025-02-10
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm255949d1_8k.htm   iXBRL 8-K 25650
2 EXHIBIT 99.1 tm255949d1_ex99-1.htm EX-99.1 14669
6 GRAPHIC tm255949d1_ex99-1img01.jpg GRAPHIC 13810
  Complete submission text file 0001104659-25-010729.txt   238727

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA iova-20250210.xsd EX-101.SCH 3003
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE iova-20250210_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE iova-20250210_pre.xml EX-101.PRE 22351
17 EXTRACTED XBRL INSTANCE DOCUMENT tm255949d1_8k_htm.xml XML 3702
Mailing Address 825 INDUSTRIAL ROAD 4TH FLOOR SAN CARLOS CA 94070
Business Address 825 INDUSTRIAL ROAD 4TH FLOOR SAN CARLOS CA 94070 6502607120
IOVANCE BIOTHERAPEUTICS, INC. (Filer) CIK: 0001425205 (see all company filings)

EIN.: 753254381 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36860 | Film No.: 25603652
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)